International: +1-347-960-6455
Monoclonal Antibodies Therapeutics - Pipeline Analysis 2018

Monoclonal Antibodies Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10186 Report Type: Molecule-Type Pipeline Reports Available format: 
Therapeutic Area(s): Others
Select License Type

Monoclonal antibodies are the prominent therapeutic agents in biomedical research, as they are implemented in the diagnosis and treatment of various diseases areas, including cancer, infectious diseases, immunology, and cardiovascular disorders. The antibodies are produced from cell lines, which are obtained from the immunized animals. The animals are immunized with the substance that is being studied. After that, the fusion of immunized animal’s myeloma cells with the B-cells produces the desired cell lines. The monoclonal antibodies are formed by either in vitro culture of those desired cell lines or by injecting the cell lines into the peritoneal cavity of the prepared mouse (the method is known as mouse ascites method). The usage of monoclonal antibodies in biomedical research has been extensive and is anticipated to be significant in future for the identification of carbohydrates, proteins, and nucleic acids. The advancements in biological science have led to an understanding of the host response to the infectious and toxic agents, transplanted organs, endogenous antigens, and tumours. In regard to the diagnosis and treatment, monoclonal antibodies have shown an exquisite specificity toward the antigens.

Morphotek Inc. is the process of developing farletuzumab as a humanized IgG1 antibody targeting folate receptor alpha for the treatment of patients with relapsed platinum-sensitive ovarian cancer, non-small cell lung cancer (NSCLC). Novimmune SA is developing emapalumab for the treatment of hemophagocytic lymphohistiocytosis. Some of the companies developing monoclonal antibodies include F. Hoffman-La-Roche Ltd. and Jounce Therapeutics Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.